---
title: "Barclays Reaffirms Their Buy Rating on Insmed (INSM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285704129.md"
description: "Barclays analyst Eliana Merle has reaffirmed a Buy rating on Insmed (INSM) with a price target of $237.00. Merle, a 3-star analyst with a 41.22% success rate, focuses on the Healthcare sector. Additionally, TD Cowen also maintained a Buy rating on Insmed, setting a price target of $243.00."
datetime: "2026-05-08T10:03:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285704129.md)
  - [en](https://longbridge.com/en/news/285704129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285704129.md)
---

# Barclays Reaffirms Their Buy Rating on Insmed (INSM)

Barclays analyst Eliana Merle maintained a Buy rating on Insmed today and set a price target of $237.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Merle is a 3-star analyst with an average return of 3.8% and a 41.22% success rate. Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and BioMarin Pharmaceutical.

In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $243.00 price target.

### Related Stocks

- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PTH.US](https://longbridge.com/en/quote/PTH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | INSM Stock News](https://longbridge.com/en/news/288708068.md)
- [Westfield Capital Management Co. LP Sells 55,406 Shares of Insmed, Inc. $INSM](https://longbridge.com/en/news/288855190.md)
- [Insmed Chair, CEO Sold Shares Worth Over $777K](https://longbridge.com/en/news/288902443.md)
- [ABN Amro Investment Solutions Takes Position in Insmed, Inc. $INSM](https://longbridge.com/en/news/287451516.md)
- [Wealthfront Advisers LLC Takes $1.74 Million Position in Insmed, Inc. $INSM](https://longbridge.com/en/news/284995222.md)